Twice as Effective? Pressurized Intra-Thoracic Aerosol Chemotherapy: New Frontiers in Pleural Mesothelioma.

Q1 Medicine

Medical sciences (Basel, Switzerland) Pub Date : 2025-06-02 DOI:10.3390/medsci13020072

Maria Giovanna Mastromarino, Elena Guerrini, Raffaele Guerrieri, Gianmarco Elia, Alessandra Lenzini, Vittorio Aprile, Greta Alì, Stylianos Korasidis, Marcello Carlo Ambrogi, Marco Lucchi

{"title":"Twice as Effective? Pressurized Intra-Thoracic Aerosol Chemotherapy: New Frontiers in Pleural Mesothelioma.","authors":"Maria Giovanna Mastromarino, Elena Guerrini, Raffaele Guerrieri, Gianmarco Elia, Alessandra Lenzini, Vittorio Aprile, Greta Alì, Stylianos Korasidis, Marcello Carlo Ambrogi, Marco Lucchi","doi":"10.3390/medsci13020072","DOIUrl":null,"url":null,"abstract":"<p><p>Pressurized intra-thoracic aerosol chemotherapy (PITAC) is a novel and promising strategy for the treatment of malignant pleural effusion (MPE). PITAC enables effective pleurodesis while potentially exerting an antineoplastic effect by delivering chemotherapeutic agents as a therapeutic aerosol into the thoracic cavity via a nebulizer. Our preliminary study involved nine patients with unresectable pleural mesothelioma (PM) treated with PITAC. Among them, one case was particularly emblematic for demonstrating notable oncological improvements in addition to well-known palliative benefits. This patient underwent two PITAC procedures, one year apart, without perioperative complications. Redo pleural biopsies from both previous and new sites revealed only fibrous tissue and inflammatory cells, with no evidence of malignancy. Beyond achieving pleurodesis, PITAC-by combining cytotoxic and sclerosing effects-may offer effective local antineoplastic control and represent a promising avenue for enhancing loco-regional therapy in PM.</p>","PeriodicalId":74152,"journal":{"name":"Medical sciences (Basel, Switzerland)","volume":"13 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12195480/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical sciences (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/medsci13020072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Pressurized intra-thoracic aerosol chemotherapy (PITAC) is a novel and promising strategy for the treatment of malignant pleural effusion (MPE). PITAC enables effective pleurodesis while potentially exerting an antineoplastic effect by delivering chemotherapeutic agents as a therapeutic aerosol into the thoracic cavity via a nebulizer. Our preliminary study involved nine patients with unresectable pleural mesothelioma (PM) treated with PITAC. Among them, one case was particularly emblematic for demonstrating notable oncological improvements in addition to well-known palliative benefits. This patient underwent two PITAC procedures, one year apart, without perioperative complications. Redo pleural biopsies from both previous and new sites revealed only fibrous tissue and inflammatory cells, with no evidence of malignancy. Beyond achieving pleurodesis, PITAC-by combining cytotoxic and sclerosing effects-may offer effective local antineoplastic control and represent a promising avenue for enhancing loco-regional therapy in PM.

查看原文本刊更多论文

两倍的效果？胸膜间皮瘤治疗的新领域。

加压胸腔内气溶胶化疗（PITAC）是一种治疗恶性胸腔积液（MPE）的新方法。PITAC通过喷雾器将化疗药物作为治疗气雾剂送入胸腔，从而实现有效的胸膜切除术，同时潜在地发挥抗肿瘤作用。我们的初步研究包括9例不可切除的胸膜间皮瘤（PM）患者用PITAC治疗。其中，一个病例特别具有象征意义，除了众所周知的姑息治疗益处外，还显示出显着的肿瘤学改善。该患者接受了两次PITAC手术，间隔一年，无围手术期并发症。既往和新发胸膜活检均仅发现纤维组织和炎症细胞，未发现恶性肿瘤。除了实现胸膜切除术外，pitac -通过结合细胞毒性和硬化作用-可能提供有效的局部抗肿瘤控制，并代表了加强PM局部区域治疗的有希望的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊